- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Maze Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| Fr | Maze Therapeutics stock hugs flat line following $140M IPO | 1 | Seeking Alpha | ||
| Fr | Maze Therapeutics IPO startet mit leichtem Plus | 1 | Investing.com Deutsch | ||
| Fr | Maze Therapeutics IPO opens trading modestly higher | 1 | Investing.com | ||
| Fr | Maze Therapeutics Opens At $16.12, IPO Priced At $16 | 2 | Investing.com | ||
| Fr | Precision medicine biotech Maze Therapeutics prices upsized IPO at the $16 midpoint | 2 | Renaissance Capital | ||
| Fr | Busy day for biotech IPOs as Metsera, Maze Therapeutics go public with offerings totaling nearly $400M | 1 | FierceBiotech | ||
| Fr | Two more biotechs, Metsera and Maze Therapeutics, cross IPO finish line | 7 | pharmaphorum | ||
| MAZE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Maze Therapeutics Prices Upsized IPO Of 8.75 Mln Shares At $16.00/shr | 392 | AFX News | WASHINGTON (dpa-AFX) - Maze Therapeutics Inc. (MAZE) announced that it has priced its upsized initial public
offering of 8.75 million shares of its common stock at a public offering price... ► Artikel lesen | |
| Fr | Metsera, Maze Therapeutics secure combined $415 million in IPOs | 1 | BioPharma Dive | ||
| Fr | Maze Therapeutics, Inc.: Maze Therapeutics Announces Pricing of Upsized Initial Public Offering | 61 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop... ► Artikel lesen | |
| Mo | Maze Therapeutics, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| Mo | Maze Therapeutics rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing | 1 | FierceBiotech | ||
| Mo | Precision medicine biotech Maze Therapeutics sets terms for $125 million IPO | 3 | Renaissance Capital | ||
| Mo | Maze Therapeutics Files for 7.8M Share IPO at $15-$17/sh | 1 | Investing.com | ||
| Mo | Maze Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 09.01. | Kidney disease drug developer Maze Therapeutics files for $100M IPO | 1 | Seeking Alpha | ||
| 08.01. | Kidney disease drugmaker Maze Therapeutics files for IPO | 1 | BioPharma Dive | ||
| 08.01. | Precision medicine biotech Maze Therapeutics files for a $100 million IPO | 3 | Renaissance Capital | ||
| 08.01. | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing | 1 | Reuters |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 57,50 | +0,54 % | Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky Sells 82,056 Shares | ||
| IMMUNOVANT | 21,740 | -1,50 % | Here's Why Immunovant, Inc. (IMVT) Will Double in 2025 | ||
| RECURSION PHARMACEUTICALS | 7,240 | -5,85 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
| IMMUNOME | 11,030 | +4,95 % | Immunome Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 37,500 | +0,73 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025 | ||
| AVIDITY BIOSCIENCES | 32,930 | +0,92 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| EVOTEC | 8,650 | +0,82 % | BioTech - jetzt geht's los! 100 % Chancen für Evotec, BioNxt, Bayer, Formycon und Novo Nordisk! | Der DAX 40-Index erreichte in der letzten Woche mit 21.520 Punkten ein neues Allzeithoch. Das klingt auf den ersten Blick komisch, denn die Hälfte aller Werte krebst an mehrjährigen Tiefstständen. Zugpferde... ► Artikel lesen | |
| JANUX THERAPEUTICS | 43,480 | -2,92 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 53,76 | +3,90 % | A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts | ||
| ARS PHARMACEUTICALS | 13,020 | -8,89 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
| 89BIO | 9,600 | -0,52 % | 89bio, Inc. - 8-K, Current Report | ||
| DYNE THERAPEUTICS | 14,220 | +0,57 % | Dyne Therapeutics (NASDAQ:DYN) Sees Large Volume Increase - What's Next? | ||
| BIONTECH | 118,90 | -0,34 % | JPMORGAN stuft Biontech auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Biontech von 122 auf 120 US-Dollar gesenkt und die Einstufung auf "Neutral" belassen. Ihre aktualisierten Schätzungen für die... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,400 | +0,87 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 45,990 | -2,40 % | MoonLake Immunotherapeutics AG: MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody sonelokimab | New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar... ► Artikel lesen |
Das Unternehmen MAZE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 15,950 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAZE THERAPEUTICS INC finden Sie auf Wallstreet Online.
